Actively Recruiting
Long-Term Safety and Effectiveness Study of Pozelimab and Cemdisiran Combination Therapy in Adults with Paroxysmal Nocturnal Hemoglobinuria
Led by Regeneron Pharmaceuticals · Updated on 2026-09-28
202
Participants Needed
48
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying an experimental combination of two drugs, pozelimab and cemdisiran, for adults with paroxysmal nocturnal hemoglobinuria PNH. This study aims to evaluate the long-term safety and effectiveness of this drug combination. It also investigates how the drugs affect the body over time, including possible side effects, drug levels in the blood, and whether the body develops antibodies against the drugs. The study includes two groups patients who completed treatment in a previous related study and patients with a specific genetic variation C5 polymorphism that makes them resistant to other treatments. Participants receive pozelimab with an initial intravenous loading dose on Day 1, followed by ongoing treatment with both study drugs as per the study protocol. The study is open-label and non-randomized. Participants will attend clinic visits and undergo various assessments throughout the study, including blood tests to measure lactate dehydrogenase LDH levels and monitor hemolysis, transfusion needs, hemoglobin levels, fatigue, physical function, and quality of life. Safety is closely monitored by tracking adverse events. The study lasts up to 108 weeks, allowing researchers to observe long-term treatment effects and safety.
CONDITIONS
Brief Title
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here